Design and optimization of N-(3-((4-(1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)amide derivatives as potent anti-inflammatory agents against LPS-induced acute lung injury

Key Points

• N-(3-((4-(1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)amide derivatives showed significant anti-inflammatory effects, aiding in lung injury reduction.
• The most effective compound reduced inflammation markers by 55% in animal models exposed to LPS.
• Optimization involved chemical modifications to enhance pharmacological properties through systematic design.
• These findings highlight potential new treatments for acute lung injury, warranting further clinical investigation.